Niagen Bioscience, Inc. current report, 19 October 2021

Business Context and Reporting Period

This Form 8-K Current Report was filed by ChromaDex Corporation (trading symbol: CDXC) on October 29, 2021, regarding an event that occurred on October 19, 2021. The filing addresses a change in the composition of the Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements or performance metrics.

Material Changes

The material change reported is the resignation of Tony Lau from the Board of Directors and the Compensation Committee. Mr. Lau's resignation is effective as of a date to be determined. The filing explicitly states that the resignation is not due to any disagreement with the Company regarding its operations, policies, or practices.

Outlook and Management Commentary

Mr. Lau serves as the director nominated by Champion River Ventures Limited ("Champion River") under a 2017 Securities Purchase Agreement. Champion River is affiliated with Horizon Ventures Limited, where Mr. Lau was previously employed. Following Mr. Lau's resignation from Horizon, Champion River intends to nominate a replacement director to the Board in accordance with its rights under the Purchase Agreement. No financial guidance or risk factors were disclosed in this specific filing.

Key Facts for Investor Verification

  • Confirm the effective date of Tony Lau's resignation once determined.
  • Verify the identity of the new director nominee to be appointed by Champion River Ventures Limited.
  • Review the 2017 Securities Purchase Agreement to understand the specific rights and obligations regarding board representation.
  • Check subsequent filings for any updates on the Compensation Committee composition.